US20070149522A1 - Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide - Google Patents
Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide Download PDFInfo
- Publication number
- US20070149522A1 US20070149522A1 US10/538,342 US53834203A US2007149522A1 US 20070149522 A1 US20070149522 A1 US 20070149522A1 US 53834203 A US53834203 A US 53834203A US 2007149522 A1 US2007149522 A1 US 2007149522A1
- Authority
- US
- United States
- Prior art keywords
- chlorothiophene
- carboxamide
- oxo
- reacting
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PMRGCQBQXKKISO-MRXNPFEDSA-N CC1=CC=C(C(=O)NC[C@H](O)CNC2=CC=C(N3CCOCC3=O)C=C2)S1 Chemical compound CC1=CC=C(C(=O)NC[C@H](O)CNC2=CC=C(N3CCOCC3=O)C=C2)S1 PMRGCQBQXKKISO-MRXNPFEDSA-N 0.000 description 3
- TVLWSTXKNMRJJL-SSDOTTSWSA-N CC1=CC=C(C(=O)NC[C@H](O)CBr)S1 Chemical compound CC1=CC=C(C(=O)NC[C@H](O)CBr)S1 TVLWSTXKNMRJJL-SSDOTTSWSA-N 0.000 description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N O=C(NC[C@H]1CN(C2=CC=C(N3CCOCC3=O)C=C2)C(=O)O1)C1=CC=C(Cl)S1 Chemical compound O=C(NC[C@H]1CN(C2=CC=C(N3CCOCC3=O)C=C2)C(=O)O1)C1=CC=C(Cl)S1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 2
- KECLKYMGKLKNQG-ZSXLTIADSA-H C.I.I[IH]I.I[V](I)I.I[V]I.NC1=CC=C(N2CCOCC2=O)C=C1.O=C(Cl)C1=CC=C(Cl)S1.O=C(NCC(O)CNC1=CC=C(N2CCOCC2=O)C=C1)C1=CC=C(Cl)S1.O=C(NC[C@H](O)CBr)C1=CC=C(Cl)S1.O=C(NC[C@H](O)CO)C1=CC=C(Cl)S1.OC[C@@H](O)CNCl.[V]I Chemical compound C.I.I[IH]I.I[V](I)I.I[V]I.NC1=CC=C(N2CCOCC2=O)C=C1.O=C(Cl)C1=CC=C(Cl)S1.O=C(NCC(O)CNC1=CC=C(N2CCOCC2=O)C=C1)C1=CC=C(Cl)S1.O=C(NC[C@H](O)CBr)C1=CC=C(Cl)S1.O=C(NC[C@H](O)CO)C1=CC=C(Cl)S1.OC[C@@H](O)CNCl.[V]I KECLKYMGKLKNQG-ZSXLTIADSA-H 0.000 description 1
- JHEQYMDHVMJQPF-ZETCQYMHSA-N CC1=CC=C(C(=O)NC[C@H](O)CO)S1 Chemical compound CC1=CC=C(C(=O)NC[C@H](O)CO)S1 JHEQYMDHVMJQPF-ZETCQYMHSA-N 0.000 description 1
- MZKDAIDUBDLIQJ-MKCDCBMOSA-M I.II.I[IH]I.NC1=CC=C(N2CCOCC2=O)C=C1.NC[C@H]1CN(C2=CC=C(N3CCOCC3=O)C=C2)C(=O)O1.O=C(Cl)C1=CC=C(Cl)S1.O=C(NC[C@H]1CN(C2=CC=C(N3CCOCC3=O)C=C2)C(=O)O1)C1=CC=C(Cl)S1.O=C1C2=C(C=CC=C2)C(=O)N1C[C@H]1CO1.O=C1COCCN1C1=CC=C(N2C[C@H](CN3C(=O)C4=C(C=CC=C4)C3=O)OC2=O)C=C1.O=C1COCCN1C1=CC=C(NC[C@@H](O)CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1.[V]I Chemical compound I.II.I[IH]I.NC1=CC=C(N2CCOCC2=O)C=C1.NC[C@H]1CN(C2=CC=C(N3CCOCC3=O)C=C2)C(=O)O1.O=C(Cl)C1=CC=C(Cl)S1.O=C(NC[C@H]1CN(C2=CC=C(N3CCOCC3=O)C=C2)C(=O)O1)C1=CC=C(Cl)S1.O=C1C2=C(C=CC=C2)C(=O)N1C[C@H]1CO1.O=C1COCCN1C1=CC=C(N2C[C@H](CN3C(=O)C4=C(C=CC=C4)C3=O)OC2=O)C=C1.O=C1COCCN1C1=CC=C(NC[C@@H](O)CN2C(=O)C3=C(C=CC=C3)C2=O)C=C1.[V]I MZKDAIDUBDLIQJ-MKCDCBMOSA-M 0.000 description 1
- ONXXLSCGXIDHCR-IZBCQXQASA-L II.O=C1NC(=O)C2=C1C=CC=C2.O=COO[K].OC[C@H](O)CCl.OC[C@H]1CO1.[KH].[V].[V]I Chemical compound II.O=C1NC(=O)C2=C1C=CC=C2.O=COO[K].OC[C@H](O)CCl.OC[C@H]1CO1.[KH].[V].[V]I ONXXLSCGXIDHCR-IZBCQXQASA-L 0.000 description 1
- MHCRLDZZHOVFEE-UHFFFAOYSA-N NC1=CC=C(N2CCOCC2=O)C=C1 Chemical compound NC1=CC=C(N2CCOCC2=O)C=C1 MHCRLDZZHOVFEE-UHFFFAOYSA-N 0.000 description 1
- BMPDCQVRKDNUAP-UHFFFAOYSA-N O=C(Cl)C1=CC=C(Cl)S1 Chemical compound O=C(Cl)C1=CC=C(Cl)S1 BMPDCQVRKDNUAP-UHFFFAOYSA-N 0.000 description 1
- OKMRQXXUAFSBCM-CQSZACIVSA-N O=C(NC[C@H](O)CNC1=CC=C(N2CCOCC2=O)C=C1)C1=CC=C(Cl)S1 Chemical compound O=C(NC[C@H](O)CNC1=CC=C(N2CCOCC2=O)C=C1)C1=CC=C(Cl)S1 OKMRQXXUAFSBCM-CQSZACIVSA-N 0.000 description 1
- ORZUFCRGSHHENL-VKHMYHEASA-N OC[C@@H](O)CNCl Chemical compound OC[C@@H](O)CNCl ORZUFCRGSHHENL-VKHMYHEASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a process for preparing 5-chloro-N-( ⁇ (5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl ⁇ methyl)-2-thiophene-carboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-aminopropane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.
- the compound of the formula (I) acts as an inhibitor of clotting factor Xa and may be used as an agent for the prophylaxis and/or treatment of thromboembolic disorders, especially myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transient ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses.
- myocardial infarction especially myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transient ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses.
- WO-A 01/47919 also describes a method for preparing the compound of the formula (I) starting from 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione (II), 4-(4-aminophenyl)-3-morpholinone (III) and 5-chlorothiophene-2-carbonyl chloride (IV):
- the epoxyphthalimide (II) is prepared by reacting (2S)-1-chloropropane-2,3-diol (V) with potassium carbonate via the stage of (S)-glycidol (VI) and subsequent Mitsunobu reaction with phthalimide:
- the glycidol (VI), especially in relatively large amounts, is polymerization-sensitive and thus not storage-stable, additionally toxic and potentially carcinogenic.
- the Mitsunobu reaction in the preparation of compound (II) is technically costly and inconvenient, one reason being that racemization occurs readily in relatively large batches.
- Another reason is that the atom economy is extremely unsatisfactory, since triphenylphosphine oxide and diisopropyl azodicarboxylate hydrazide are generated in stoichiometric amounts as waste materials.
- the nitrogen atom in the oxazolidinone ring of the target molecule (I) is introduced in phthalimide-protected form.
- the phthalic acid radical as a protecting group has to be removed in the further course of the synthesis, which means an increase in the number of stages and additional waste.
- the compound of the formula (I) can be prepared in improved yield in a shortened reaction sequence using storage-stable and less toxic starting materials, starting from 5-chlorothiophene-2-carbonyl chloride (IV), (2S)-3-aminopropane-1,2-diol hydrochloride (VII) and 4-(4-aminophenyl)-3-morpholinone (III).
- IV 5-chlorothiophene-2-carbonyl chloride
- VII (2S)-3-aminopropane-1,2-diol hydrochloride
- III 4-(4-aminophenyl)-3-morpholinone
- 5-chlorothiophene-2-carbonyl chloride (IV) is prepared from 5-chlorothiophene-2-carboxylic acid.
- Compound (IV) may be prepared under the customary reaction conditions for the preparation of carbonyl chlorides from the corresponding carboxylic acids. Preference is given to the reaction of 5-chlorothiophene-2-carboxylic acid with thionyl chloride as the chlorinating reagent in toluene as the solvent.
- the reaction (IV)+(VII) ⁇ (VIII) may be effected under the reaction conditions customary for the formation of amide bonds from the appropriate carbonyl chlorides and amines. Preference is given to a biphasic system composed of aqueous sodium hydrogencarbonate solution and 2-methyltetrahydrofuran as the organic solvent. (2S)-3-Aminopropane-1,2-diol is used in the form of the free base or in the form of the acid addition salt. Preference is given to the hydrochloride (VII) which crystallizes better than the free base and can therefore be handled readily. To increase the reaction yield, optionally either an excess of amine is used or an auxiliary base is added.
- reaction is effected generally within a temperature range of from 0° C. to 40° C., preferably of from 5° C. to 30° C.
- N—((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide (VIII) is converted to N—((S)-3-bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide (IX)
- the reaction (VIII) ⁇ (IX) is carried out with from 1 to 5, preferably from 3 to 5, in particular 4, equivalents of a solution of hydrobromic acid in acetic acid, optionally in the presence of acetic anhydride.
- the reaction temperature is between 20° C. and 80° C., preferably between 60 and 65° C.
- the amount of methanol added may be varied over a wide range; preference is given to using from 40 to 80 mol, in particular from 50 to 60 mol, of methanol per mole of (VIII).
- the solvents are distilled off, preferably under reduced pressure. The remaining distillation residue is optionally also neutralized before the filtration of the product.
- N—((S)-3-bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide (IX) is reacted with 4-(4-aminophenyl)-3-morpholinone (III) to give N— ⁇ (R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl ⁇ -5-chlorothiophene-2-carboxamide (X)
- the solvent for the reaction (IX)+(III) ⁇ (X) may be varied widely; preference is given to toluene.
- the reaction temperature is between 80° C. and 200° C.; preference is given to a range between 90° C. and 110° C.
- the reaction is effected optionally in the presence of an auxiliary base, for example triethylamine, diisopropylethylamine or collidine; preference is given to using collidine.
- the stoichiometry of the reaction and the reaction time are variable over a wide range; preference is given to a ratio of compound (IX) to compound (III) to collidine of 1.2 to 1.0 to 1.0 and a reaction time of from 4 to 8 hours, especially of from 5 to 6 hours.
- N— ⁇ (R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl ⁇ -5-chlorothiophene-2-carboxamide (X) is reacted with phosgene or a phosgene equivalent to give 5-chloro-N-( ⁇ (5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl ⁇ methyl)-2-thiophene-carboxamide (I).
- one or more equivalents of phosgene or phosgene equivalents are used in the presence of inert solvents or solvent mixtures.
- Phosgene equivalents are, for example, phosgene replacements such as di- or triphosgene, or carbon monoxide equivalents, for example N,N-carbonylbisimidazole.
- Preference is given to using from 1 to 2 equivalents, in particular from 1.1 to 1.3 equivalents, of N,N-carbonylbisimidazole in a solvent mixture of 1-methyl-2-pyrrolidone and toluene.
- a clarifying filtration and/or a recrystallization optionally follows.
- the reaction is effected generally within a temperature range of from 20° C. to 150° C., preferably of from 30° C. to 110° C., in particular of from 75° C. to 85° C.
- the individual stages of the process according to the invention may be carried out at standard, elevated or at reduced pressure (for example of from 0.5 to 5 bar). In general, standard pressure is used.
- the solvents are distilled off under reduced pressure at approx. 95 mbar.
- the remaining suspension is admixed with 50 ml of 1-butanol and 350 ml of water.
- the precipitated product is filtered off with suction, washed with water and dried.
Abstract
Description
- The present invention relates to a process for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide starting from 5-chlorothiophene-2-carbonyl chloride, (2S)-3-aminopropane-1,2-diol and 4-(4-aminophenyl)-3-morpholinone.
-
- The compound of the formula (I) acts as an inhibitor of clotting factor Xa and may be used as an agent for the prophylaxis and/or treatment of thromboembolic disorders, especially myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transient ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses.
-
-
- The process known from WO-A 01/47919 has various disadvantages which have a particularly unfavorable effect when the compound of the formula (I) is prepared on the industrial scale:
- For instance, the glycidol (VI), especially in relatively large amounts, is polymerization-sensitive and thus not storage-stable, additionally toxic and potentially carcinogenic. The Mitsunobu reaction in the preparation of compound (II) is technically costly and inconvenient, one reason being that racemization occurs readily in relatively large batches. Another reason is that the atom economy is extremely unsatisfactory, since triphenylphosphine oxide and diisopropyl azodicarboxylate hydrazide are generated in stoichiometric amounts as waste materials. In addition, the nitrogen atom in the oxazolidinone ring of the target molecule (I) is introduced in phthalimide-protected form. However, the phthalic acid radical as a protecting group has to be removed in the further course of the synthesis, which means an increase in the number of stages and additional waste.
- It is thus an object of the present invention to provide a simplified process for preparing the compound of the formula (I) in large amounts.
- It has been found that, surprisingly, the compound of the formula (I) can be prepared in improved yield in a shortened reaction sequence using storage-stable and less toxic starting materials, starting from 5-chlorothiophene-2-carbonyl chloride (IV), (2S)-3-aminopropane-1,2-diol hydrochloride (VII) and 4-(4-aminophenyl)-3-morpholinone (III). In this reaction sequence, the use of protecting groups is also avoided, which reduces the number of stages and thus shortens the reaction time.
-
- Compound (IV) may be prepared under the customary reaction conditions for the preparation of carbonyl chlorides from the corresponding carboxylic acids. Preference is given to the reaction of 5-chlorothiophene-2-carboxylic acid with thionyl chloride as the chlorinating reagent in toluene as the solvent.
-
- The reaction (IV)+(VII)→(VIII) may be effected under the reaction conditions customary for the formation of amide bonds from the appropriate carbonyl chlorides and amines. Preference is given to a biphasic system composed of aqueous sodium hydrogencarbonate solution and 2-methyltetrahydrofuran as the organic solvent. (2S)-3-Aminopropane-1,2-diol is used in the form of the free base or in the form of the acid addition salt. Preference is given to the hydrochloride (VII) which crystallizes better than the free base and can therefore be handled readily. To increase the reaction yield, optionally either an excess of amine is used or an auxiliary base is added. The addition of from 1 to 3, preferably 2, equivalents of an auxiliary base such as sodium hydrogencarbonate is preferred. The reaction is effected generally within a temperature range of from 0° C. to 40° C., preferably of from 5° C. to 30° C.
-
- The reaction (VIII)→(IX) is carried out with from 1 to 5, preferably from 3 to 5, in particular 4, equivalents of a solution of hydrobromic acid in acetic acid, optionally in the presence of acetic anhydride. The reaction temperature is between 20° C. and 80° C., preferably between 60 and 65° C. The amount of methanol added may be varied over a wide range; preference is given to using from 40 to 80 mol, in particular from 50 to 60 mol, of methanol per mole of (VIII). For the workup, the solvents are distilled off, preferably under reduced pressure. The remaining distillation residue is optionally also neutralized before the filtration of the product.
-
- The solvent for the reaction (IX)+(III)→(X) may be varied widely; preference is given to toluene. The reaction temperature is between 80° C. and 200° C.; preference is given to a range between 90° C. and 110° C. The reaction is effected optionally in the presence of an auxiliary base, for example triethylamine, diisopropylethylamine or collidine; preference is given to using collidine. The stoichiometry of the reaction and the reaction time are variable over a wide range; preference is given to a ratio of compound (IX) to compound (III) to collidine of 1.2 to 1.0 to 1.0 and a reaction time of from 4 to 8 hours, especially of from 5 to 6 hours.
- In the fifth step of the process according to the invention, N—{(R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl}-5-chlorothiophene-2-carboxamide (X) is reacted with phosgene or a phosgene equivalent to give 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide (I).
- In the reaction (X)→(I), one or more equivalents of phosgene or phosgene equivalents are used in the presence of inert solvents or solvent mixtures. Phosgene equivalents are, for example, phosgene replacements such as di- or triphosgene, or carbon monoxide equivalents, for example N,N-carbonylbisimidazole. Preference is given to using from 1 to 2 equivalents, in particular from 1.1 to 1.3 equivalents, of N,N-carbonylbisimidazole in a solvent mixture of 1-methyl-2-pyrrolidone and toluene. For purification of the product, a clarifying filtration and/or a recrystallization optionally follows. The reaction is effected generally within a temperature range of from 20° C. to 150° C., preferably of from 30° C. to 110° C., in particular of from 75° C. to 85° C.
- The individual stages of the process according to the invention may be carried out at standard, elevated or at reduced pressure (for example of from 0.5 to 5 bar). In general, standard pressure is used.
-
- The invention is illustrated in detail below by a preferred working example, to which it is not, however, restricted. Unless stated otherwise, all quantitative data relates to percentages by weight.
- 53.6 g of 5-chlorothiophene-2-carboxylic acid (commercially available) are suspended in 344 g of toluene and heated to 80° C. At this temperature, 47.2 g of thionyl chloride are added dropwise over a period of 20 minutes, then the mixture is stirred at from 75 to 80° C. for 30 minutes and then at reflux temperature for two hours until completion of gas evolution. After cooling, the reaction mixture is concentrated to a volume of approx. 200 ml at from 30 to 35° C. and a pressure of from 40 to 48 mbar. The thus obtained solution of the acid chloride in toluene is reacted directly in the next stage.
- 461 g of sodium hydrogencarbonate and 350 g of (2S)-3-aminopropane-1,2-diol hydrochloride (VII) (commercially available) are initially charged at from 13 to 15° C. in 2.1 l of water and admixed with 950 ml of 2-methyltetrahydrofuran. 535.3 g of 5-chlorothiophene-2-carbonyl chloride (approx. 93%) in 180 ml of toluene are added dropwise to this mixture with cooling at from 15 to 18° C. over a period of two hours. For workup, the phases are separated and the organic phase is admixed in several steps with a total of 1.5 l of toluene. The precipitated product is filtered off with suction, washed with ethyl acetate and dried.
- Yield: 593.8 g; corresponds to 91.8% of theory.
- Melting point: 114 to 114.5° C.
- 301.7 ml of a 33% solution of hydrobromic acid in acetic acid are added to a suspension of 100 g of N—((S)-2,3-dihydroxypropyl)-5-chlorothiophene-2-carboxamide (VIII) in 250 ml of glacial acetic acid at from 21 to 26° C. over a period of 30 minutes. Subsequently, 40 ml of acetic anhydride are added and the reaction mixture is stirred at from 60 to 65° C. for three hours. At 20 to 25° C., 960 ml of methanol are then added over a period of 30 minutes. The reaction mixture is stirred under reflux for 2.5 hours and then overnight at from 20 to 25° C. For workup, the solvents are distilled off under reduced pressure at approx. 95 mbar. The remaining suspension is admixed with 50 ml of 1-butanol and 350 ml of water. The precipitated product is filtered off with suction, washed with water and dried.
- Yield: 89.8 g; corresponds to 70.9% of theory.
- Melting point: 120° C.
- 55 g of N—((S)-3-bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide (IX) and 29.4 g of 4-(4-aminophenyl)-3-morpholinone (III) (a preparation method is described, for example, in WO-A 01/47919 on pages 55 to 57) are suspended at from 20 to 25° C. in 500 ml of toluene and admixed with 18.5 g of collidine and 10 ml of ethanol. The reaction mixture is heated to from 103 to 105° C. for 6 hours and then admixed while hot with 50 ml of 1-butanol. After cooling to 30° C., the precipitated reaction product is filtered off with suction, washed with toluene and water and dried.
- Yield: 42.0 g; corresponds to 61.8% of theory.
- Melting point: 198.5° C.
- 25 g of N—{(R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]propyl}-5-chlorothiophene-2-carboxamide (X) are suspended at from 20 to 25° C. in 250 ml of toluene and admixed with 37.5 ml of 1-methyl-2-pyrrolidone and 11.9 g of N,N-carbonyldiimidazole. The reaction mixture is heated to from 80 to 83° C. for 20 minutes and subsequently heated to 115° C. for one hour. After cooling to 20° C., the precipitated reaction product is filtered off with suction, washed twice with 25 ml each time of water and dried at 60° C. under reduced pressure.
- Yield: 23.7 g; corresponds to 91.5% of theory.
- Melting point: 230° C.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/556,158 US8106192B2 (en) | 2003-01-07 | 2009-09-09 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10300111.5 | 2003-01-07 | ||
DE10300111A DE10300111A1 (en) | 2003-01-07 | 2003-01-07 | Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide |
PCT/EP2003/014871 WO2004060887A1 (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/014871 A-371-Of-International WO2004060887A1 (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/556,158 Division US8106192B2 (en) | 2003-01-07 | 2009-09-09 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070149522A1 true US20070149522A1 (en) | 2007-06-28 |
Family
ID=32519617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/538,342 Abandoned US20070149522A1 (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
US12/556,158 Active 2024-06-25 US8106192B2 (en) | 2003-01-07 | 2009-09-09 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/556,158 Active 2024-06-25 US8106192B2 (en) | 2003-01-07 | 2009-09-09 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
Country Status (8)
Country | Link |
---|---|
US (2) | US20070149522A1 (en) |
EP (1) | EP1583761B1 (en) |
JP (1) | JP4667044B2 (en) |
AU (1) | AU2003296728A1 (en) |
CA (1) | CA2512504C (en) |
DE (2) | DE10300111A1 (en) |
ES (1) | ES2360097T3 (en) |
WO (1) | WO2004060887A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040242660A1 (en) * | 2001-06-20 | 2004-12-02 | Alexander Straub | Substituted oxazolidinones for combinational therapy |
US20070026065A1 (en) * | 2004-12-24 | 2007-02-01 | Bayer Healthcare Ag | Solid, modified-release pharmaceutical dosage forms which can be administered orally |
US20080090815A1 (en) * | 1999-12-24 | 2008-04-17 | Alexander Straub | Substituted oxazolidinones and their use in the field of blood coagulation |
US20080306070A1 (en) * | 2005-10-04 | 2008-12-11 | Bayer Healthcare Ag | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders |
US20090004265A1 (en) * | 2005-01-31 | 2009-01-01 | Bayer Healthcare Ag | Prevention and Treatment of Thromboembolic Disorders |
US20090036504A1 (en) * | 2005-09-23 | 2009-02-05 | Bayer Healthcare Ag | 2-Aminoethoxyacetic Acid Derivatives and Their Use |
US20090048173A1 (en) * | 2004-05-13 | 2009-02-19 | Wolfgang Eisert | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors |
US20100081807A1 (en) * | 2003-01-07 | 2010-04-01 | Bayer Healthcare Ag | Method for producing 5-cloro-n-(methyl)-2-thiophenecarboxamide |
US20100120718A1 (en) * | 2006-11-02 | 2010-05-13 | Bayer Schering Pharma Aktiengesellschaft | Combination therapy of substituted oxazolidinones |
US20100152189A1 (en) * | 2005-10-04 | 2010-06-17 | Bayer Healthcare Ag | Novel polymorphous form and the amorphous form of 5-chloro-n-({ (5s)-2-oxo-3[4-(3-oxo-4-morpholinyl(-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
WO2012051692A1 (en) | 2010-10-18 | 2012-04-26 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
CN102753537A (en) * | 2010-02-10 | 2012-10-24 | 桑多斯股份公司 | Method for the preparation of rivaroxaban |
CN102822167A (en) * | 2010-01-04 | 2012-12-12 | 埃南蒂亚有限公司 | Process for the preparation of rivaroxaban and intermediates thereof |
WO2013152168A1 (en) | 2012-04-06 | 2013-10-10 | Indiana University Research And Technology Corporation | Processes for preparing rivaroxaban |
CN103351385A (en) * | 2013-06-28 | 2013-10-16 | 浙江燎原药业有限公司 | Preparation method for rivaroxaban intermediate |
WO2013164833A1 (en) * | 2012-05-02 | 2013-11-07 | Symed Labs Limited | Improved process for preparing rivaroxaban using novel intermediates |
US8586082B2 (en) | 2005-10-04 | 2013-11-19 | Bayer Intellectual Property Gmbh | Solid orally administerable pharmaceutical dosage forms with rapid active principle release |
CN103524447A (en) * | 2013-10-24 | 2014-01-22 | 山东铂源药业有限公司 | Method for synthesizing rivaroxaban intermediate 4-(4-aminophenyl)-3-molindone |
CN103724336A (en) * | 2013-12-24 | 2014-04-16 | 悦康药业集团有限公司 | Synthesis method of novel anticoagulation drug |
CN103864771A (en) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | Rivaroxaban preparation method |
WO2016045586A1 (en) * | 2014-09-26 | 2016-03-31 | 华北制药集团新药研究开发有限责任公司 | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof |
US9402851B2 (en) | 2003-11-27 | 2016-08-02 | Bayer Intellectual Property Gmbh | Process for the preparation of a solid, orally administrable pharmaceutical composition |
US9556163B2 (en) | 2011-05-06 | 2017-01-31 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of a rivaroxaban and intermediates formed in said process |
CN109280053A (en) * | 2018-10-11 | 2019-01-29 | 东南大学 | Razaxaban oxazolidine impurity reference substance and preparation method thereof |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004002044A1 (en) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | manufacturing |
EP1571154A1 (en) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Beta-aminoacid-derivatives as factor Xa inhibitors |
DE102005047564A1 (en) | 2005-10-04 | 2007-05-31 | Bayer Healthcare Ag | New forms of specific substituted thiophene carboxamide (rivaroxaban), useful for prevention and treatment of thromboembolic disease, have higher solubility than known modifications |
DE102007028320A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
DE102007032347A1 (en) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl prodrugs |
DE102007032345A1 (en) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl prodrugs |
DE102007037373A1 (en) | 2007-08-06 | 2009-02-19 | Schebo Biotech Ag | New oxazolidinone derivatives are factor Xa inhibitors useful to treat e.g. acute coronary syndrome, myocardial infarction, angina pectoris, reocclusion, restenosis, stroke, artrial fibrillation, arrhythmia and blood clotting disorder |
WO2009018807A1 (en) * | 2007-08-06 | 2009-02-12 | Schebo Biotech Ag | Novel pharmaceuticals, method for the production thereof, and use thereof in therapy |
US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
PL2459555T3 (en) | 2009-07-31 | 2022-03-28 | Krka, D.D., Novo Mesto | Processes for crystallization of rivaroxaban |
EP2404920A1 (en) | 2010-07-06 | 2012-01-11 | Sandoz AG | Crystalline form of Rivaroxaban dihydrate |
CN104693139B (en) * | 2011-01-07 | 2017-04-19 | 浙江九洲药业股份有限公司 | Novel technology for synthesizing Rivaroxaban intermediate |
EP2697209B1 (en) | 2011-04-11 | 2015-09-23 | Sandoz AG | Method for the preparation of substituted oxazolidinones |
ES2395304B1 (en) | 2011-05-20 | 2014-01-16 | Interquim, S.A. | PROCEDURE FOR OBTAINING A THIOPHEN-2-CARBOXAMIDE. |
WO2013098833A2 (en) | 2011-09-08 | 2013-07-04 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
HU230734B1 (en) | 2011-10-10 | 2017-12-28 | EGIS Gyógyszergyár Nyrt | Cocrystals of rivaroxaban for producing pharmaceutical compositions |
CZ2012111A3 (en) | 2012-02-16 | 2013-08-28 | Zentiva, K.S. | Process for preparing rivaroxaban based on the use of (S)-epichlorohydrin |
CZ2012114A3 (en) | 2012-02-17 | 2013-02-20 | Zentiva, K.S. | Process for preparing rivaroxaban based on saving of 1,1?-carbonyldiimidazole |
CN103288814B (en) | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | A kind of preparation method of Rivaroxaban intermediate |
AU2013250801A1 (en) * | 2012-04-16 | 2014-11-06 | Sun Pharmaceutical Industries Limited | Process for the preparation of rivaroxaban and intermediates thereof |
WO2013175431A1 (en) * | 2012-05-24 | 2013-11-28 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
US20150218145A1 (en) | 2012-09-26 | 2015-08-06 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
ES2647607T3 (en) | 2012-12-21 | 2017-12-22 | Farma Grs, D.O.O. | Procedure for the preparation of rivaroxaban |
US9359341B2 (en) | 2012-12-26 | 2016-06-07 | Wanbury Ltd. | Aldehyde derivative of substitute oxazolidinones |
PT2895176T (en) | 2012-12-26 | 2017-01-27 | Wanbury Ltd | Rivaroxaban intermediate and preparation thereof |
IN2013MU01113A (en) | 2013-03-25 | 2015-06-19 | Glenmark Generics Ltd | |
WO2015011617A1 (en) | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
IN2013MU02699A (en) | 2013-08-19 | 2015-06-19 | Amneal Pharmaceuticals Llc | |
CN104098558B (en) * | 2014-07-22 | 2016-07-06 | 常州市第四制药厂有限公司 | Amides compound and preparation method thereof |
EP3186246A1 (en) | 2014-08-25 | 2017-07-05 | Cipla Limited | Process for the preparation of rivaroxaban |
EA034656B1 (en) | 2014-10-22 | 2020-03-03 | Закляды Фармацеутычне Польфарма С.А | Process for preparing a polymorph of rivaroxaban |
KR101811123B1 (en) | 2016-02-19 | 2017-12-20 | 일동제약(주) | Novel morpholine diphosphate salt, and method for manufacturing high purity rivaroxaban using same |
CN109481445A (en) * | 2018-12-19 | 2019-03-19 | 黄泳华 | Composition containing morpholine ketone compounds |
GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
EP4201933A1 (en) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Crystallisation process for rivaroxaban |
Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811555A (en) * | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) * | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
US4128654A (en) * | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4250318A (en) * | 1977-08-26 | 1981-02-10 | Delalande S.A. | Novel 5-hydroxymethyl oxazolidinones, the method of preparing them and their application in therapeutics |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4705779A (en) * | 1983-03-11 | 1987-11-10 | Biogal Gyogyszergyar Of Debrecen And Alkaloida Vegyeszeti Gyar Of Tiszavasvari | Pharmaceutical compositions of anti-pancreatic inflammatory effect |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US4977173A (en) * | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
US5002937A (en) * | 1988-07-05 | 1991-03-26 | Boehringer Mannheim Gmbh | Diphosphonic acid compounds and use for calcium metabolism disorders |
US5254577A (en) * | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5349045A (en) * | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
US5532255A (en) * | 1993-05-01 | 1996-07-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Adhesion receptor antagonists |
US5561148A (en) * | 1993-09-23 | 1996-10-01 | Merck Patent Gesellschaft Mit Beshrankter Haftung | Adhesion receptor antagonists III |
US5654428A (en) * | 1991-11-01 | 1997-08-05 | Pharmacia & Upjohn Company | Substituted heteroarylphenyloxazolidinones |
US5656571A (en) * | 1995-04-05 | 1997-08-12 | Deerpoint Industries, Inc. | Polyolefinic adjuvants |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
US5792765A (en) * | 1996-02-06 | 1998-08-11 | Bayer Aktiengesellschaft | Substituted oxazolidinones |
US5827857A (en) * | 1996-01-16 | 1998-10-27 | Bayer Aktiengesellschaft | Pyrido-fused thienyl- and furanyl-oxazolidinones |
US5910504A (en) * | 1995-02-03 | 1999-06-08 | Pharmacia & Upjohn | Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials |
US5922708A (en) * | 1996-02-06 | 1999-07-13 | Bayer Aktiengesellschaft | Heteroaryl-oxazolidinones |
US5935724A (en) * | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US5972947A (en) * | 1995-07-07 | 1999-10-26 | Roche Diagnostics Gmbh | Oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds |
US5977373A (en) * | 1997-07-11 | 1999-11-02 | Pharmacia & Upjohn Company | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents |
US5998406A (en) * | 1997-11-12 | 1999-12-07 | Pharmacia & Upjohn Company | Oxazolidinone derivatives and pharmaceutical compositions |
US6069160A (en) * | 1995-04-21 | 2000-05-30 | Bayer Aktiengesellschaft | Heteroatom-containing benzocyclopentane-oxazolidinones |
US6218413B1 (en) * | 1997-05-30 | 2001-04-17 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
US6251869B1 (en) * | 1998-05-18 | 2001-06-26 | Pharmacia & Upjohn Company | Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
US6265178B1 (en) * | 1997-12-05 | 2001-07-24 | Pharmacia & Upjohn Company | Assay for determining oxazolidinone antibiotics having minimum monoamine oxidase inhibitory activity |
US6281210B1 (en) * | 1999-12-14 | 2001-08-28 | Pharmacia & Upjohn Company | Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
US6294201B1 (en) * | 1997-10-12 | 2001-09-25 | Bayer Aktiengesellschaft | Osmotic medicament releasing system |
US20010029351A1 (en) * | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US20010046987A1 (en) * | 1999-12-21 | 2001-11-29 | Hester Jackson B. | Oxazolidinones having a sulfoximine functionality |
US6458793B1 (en) * | 1997-07-29 | 2002-10-01 | Zeneca Limited | Heterocyclic derivatives which inhibit factor Xa |
US20030153610A1 (en) * | 1999-12-24 | 2003-08-14 | Alexander Straub | Substituted oxazolidinones and their in the field of blood coagulation |
US20030161882A1 (en) * | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
US20040102450A1 (en) * | 1998-01-27 | 2004-05-27 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
US20040162427A1 (en) * | 2001-03-07 | 2004-08-19 | Ulrich Rosentreter | Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
US6805881B1 (en) * | 1998-09-18 | 2004-10-19 | Bayer Aktiengesellschaft | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
US6818243B2 (en) * | 1999-12-28 | 2004-11-16 | Ajinomoto Co., Inc. | Crystals of aspartame derivative |
US20040242660A1 (en) * | 2001-06-20 | 2004-12-02 | Alexander Straub | Substituted oxazolidinones for combinational therapy |
US20050064006A1 (en) * | 2001-10-24 | 2005-03-24 | Bayer Aktiengesellschaft | Stents |
US20050182055A1 (en) * | 2004-01-15 | 2005-08-18 | Bayer Healthcare Ag | Preparation process |
US20050261502A1 (en) * | 2001-03-05 | 2005-11-24 | Ulrich Rosentreter | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
US7034017B2 (en) * | 2001-02-09 | 2006-04-25 | Bayer Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US7045631B2 (en) * | 2001-07-16 | 2006-05-16 | Bayer Aktiengesellschaft | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
US20060154969A1 (en) * | 2001-03-07 | 2006-07-13 | Ulrich Rosentreter | Adenosine receptor selective modulators |
US7078417B2 (en) * | 2001-03-30 | 2006-07-18 | Bayer Aktiengesellschaft | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations |
US7109218B2 (en) * | 2001-12-11 | 2006-09-19 | Bayer Healthcare Ag | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
US7129255B2 (en) * | 2001-03-30 | 2006-10-31 | Bayer Aktiengesellschaft | Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor |
US20070026065A1 (en) * | 2004-12-24 | 2007-02-01 | Bayer Healthcare Ag | Solid, modified-release pharmaceutical dosage forms which can be administered orally |
US20080026057A1 (en) * | 2003-11-27 | 2008-01-31 | Bayer Healthcare Ag | Process for the Preparation of a Solid, Orally Administrable Pharmaceutical Composition |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4259201A (en) * | 1979-11-09 | 1981-03-31 | The Procter & Gamble Company | Detergent composition containing organic peracids buffered for optimum performance |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
ES8506659A1 (en) | 1983-06-07 | 1985-08-01 | Du Pont | Aminomethyl oxooxazolidinyl benzene derivatives useful as antibacterial agents. |
CA1317594C (en) | 1987-10-21 | 1993-05-11 | Chung-Ho Park | Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
US5139788A (en) * | 1989-10-17 | 1992-08-18 | Ecolab Inc. | Noncontaminating antimicrobial composition |
US5264229A (en) * | 1992-04-20 | 1993-11-23 | Degussa Corporation | Shelf life extension for commercially processed poultry/fowl and seafood products using a specialized hydrogen peroxide |
SK283420B6 (en) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials |
JP3255499B2 (en) * | 1993-06-16 | 2002-02-12 | 花王株式会社 | Novel sulfonate, process for producing the same, and bleach composition containing the same |
US5362899A (en) * | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
US5374369A (en) * | 1993-10-14 | 1994-12-20 | Lever Brothers Company, Division Of Conopco, Inc. | Silver anti-tarnishing detergent composition |
US5683977A (en) * | 1995-03-06 | 1997-11-04 | Lever Brothers Company, Division Of Conopco, Inc. | Dry cleaning system using densified carbon dioxide and a surfactant adjunct |
US5698506A (en) * | 1995-05-19 | 1997-12-16 | Lever Brothers Company, Division Of Conopco, Inc. | Automatic dishwashing compositions containing aluminum salts |
HUP9901979A3 (en) | 1995-09-01 | 2000-03-28 | Upjohn Co | Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings and pharmaceutical compositions containing the same |
WO1997010223A1 (en) | 1995-09-15 | 1997-03-20 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone n-oxides |
US6310025B1 (en) * | 1996-03-04 | 2001-10-30 | The Procter & Gamble Company | Laundry pretreatment process and bleaching compositions |
US5968885A (en) * | 1996-04-22 | 1999-10-19 | Procter & Gamble Co. | Bleaching compositions |
MA25183A1 (en) * | 1996-05-17 | 2001-07-02 | Arthur Jacques Kami Christiaan | DETERGENT COMPOSITIONS |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
CZ299162B6 (en) | 1996-07-15 | 2008-05-07 | Sankyo Company, Limited | Pharmaceutical composition and kit |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
DE19730847A1 (en) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclically substituted oxazolidinones |
US6444634B1 (en) * | 1997-09-11 | 2002-09-03 | The Procter & Gamble Company | Bleaching compositions |
DE19755268A1 (en) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidine derivatives |
DE19802239A1 (en) | 1998-01-22 | 1999-07-29 | Bayer Ag | New oxazolidinone derivatives useful as antimicrobial agents against Gram-positive and some Gram-negative bacteria, mycobacteria, etc. |
AU764184B2 (en) | 1998-01-23 | 2003-08-14 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
DE19805117A1 (en) | 1998-02-09 | 1999-08-12 | Bayer Ag | New oxazolidinones with azole-containing tricycles |
US6346279B1 (en) * | 1998-12-14 | 2002-02-12 | Virox Technologies, Inc. | Hydrogen peroxide disinfectant with increased activity |
US6830591B1 (en) * | 2000-02-15 | 2004-12-14 | The Procter & Gamble Company | Method for the use of hydrophobic bleaching systems in textile preparation |
AU2001241507A1 (en) * | 2000-02-15 | 2001-09-12 | The Procter And Gamble Company | Method for the one step preparation of textiles |
JP4562341B2 (en) * | 2000-02-15 | 2010-10-13 | ストライク、インベストメンツ、リミテッド、ライアビリティ、カンパニー | Permanent press processing method for textiles using hydrophobic bleach |
DE10300111A1 (en) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
US7754670B2 (en) * | 2005-07-06 | 2010-07-13 | Ecolab Inc. | Surfactant peroxycarboxylic acid compositions |
DE102005045518A1 (en) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa |
DE102005047558A1 (en) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders |
DE102005047561A1 (en) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance |
DE502006009169D1 (en) | 2005-10-04 | 2011-05-05 | Bayer Schering Pharma Ag | NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID |
DE102005048824A1 (en) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Treatment and prophylaxis of microangiopathies |
-
2003
- 2003-01-07 DE DE10300111A patent/DE10300111A1/en not_active Withdrawn
- 2003-12-24 AU AU2003296728A patent/AU2003296728A1/en not_active Abandoned
- 2003-12-24 WO PCT/EP2003/014871 patent/WO2004060887A1/en active Application Filing
- 2003-12-24 CA CA2512504A patent/CA2512504C/en not_active Expired - Fee Related
- 2003-12-24 DE DE50313496T patent/DE50313496D1/en not_active Expired - Lifetime
- 2003-12-24 ES ES03814467T patent/ES2360097T3/en not_active Expired - Lifetime
- 2003-12-24 JP JP2004564216A patent/JP4667044B2/en not_active Expired - Fee Related
- 2003-12-24 US US10/538,342 patent/US20070149522A1/en not_active Abandoned
- 2003-12-24 EP EP03814467A patent/EP1583761B1/en not_active Expired - Fee Related
-
2009
- 2009-09-09 US US12/556,158 patent/US8106192B2/en active Active
Patent Citations (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811555A (en) * | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) * | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
US4250318A (en) * | 1977-08-26 | 1981-02-10 | Delalande S.A. | Novel 5-hydroxymethyl oxazolidinones, the method of preparing them and their application in therapeutics |
US4128654A (en) * | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4705779A (en) * | 1983-03-11 | 1987-11-10 | Biogal Gyogyszergyar Of Debrecen And Alkaloida Vegyeszeti Gyar Of Tiszavasvari | Pharmaceutical compositions of anti-pancreatic inflammatory effect |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4977173A (en) * | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
US5002937A (en) * | 1988-07-05 | 1991-03-26 | Boehringer Mannheim Gmbh | Diphosphonic acid compounds and use for calcium metabolism disorders |
US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5254577A (en) * | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5801246A (en) * | 1991-11-01 | 1998-09-01 | Pharmacia & Upjohn Company | Substituted heteroarylphenyloxazolidinones |
US5654428A (en) * | 1991-11-01 | 1997-08-05 | Pharmacia & Upjohn Company | Substituted heteroarylphenyloxazolidinones |
US5654435A (en) * | 1991-11-01 | 1997-08-05 | Pharmacia & Upjohn Company | Substituted arylphenyloxazolindinones |
US5756732A (en) * | 1991-11-01 | 1998-05-26 | Pharmacia & Upjohn Company | Substituted heteroarylphenyloxazolidinones |
US5929248A (en) * | 1991-11-01 | 1999-07-27 | Pharmacia & Upjohn Company | Substituted heteroarylphenyloxazolidinones |
US5349045A (en) * | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
US5532255A (en) * | 1993-05-01 | 1996-07-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Adhesion receptor antagonists |
US5561148A (en) * | 1993-09-23 | 1996-10-01 | Merck Patent Gesellschaft Mit Beshrankter Haftung | Adhesion receptor antagonists III |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
US5910504A (en) * | 1995-02-03 | 1999-06-08 | Pharmacia & Upjohn | Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials |
US5656571A (en) * | 1995-04-05 | 1997-08-12 | Deerpoint Industries, Inc. | Polyolefinic adjuvants |
US6069160A (en) * | 1995-04-21 | 2000-05-30 | Bayer Aktiengesellschaft | Heteroatom-containing benzocyclopentane-oxazolidinones |
US5972947A (en) * | 1995-07-07 | 1999-10-26 | Roche Diagnostics Gmbh | Oxazolidinone derivatives, processes for the production thereof and pharmaceutical agents containing these compounds |
US5827857A (en) * | 1996-01-16 | 1998-10-27 | Bayer Aktiengesellschaft | Pyrido-fused thienyl- and furanyl-oxazolidinones |
US5922708A (en) * | 1996-02-06 | 1999-07-13 | Bayer Aktiengesellschaft | Heteroaryl-oxazolidinones |
US5792765A (en) * | 1996-02-06 | 1998-08-11 | Bayer Aktiengesellschaft | Substituted oxazolidinones |
US5935724A (en) * | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US6218413B1 (en) * | 1997-05-30 | 2001-04-17 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
US5977373A (en) * | 1997-07-11 | 1999-11-02 | Pharmacia & Upjohn Company | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents |
US6458793B1 (en) * | 1997-07-29 | 2002-10-01 | Zeneca Limited | Heterocyclic derivatives which inhibit factor Xa |
US6294201B1 (en) * | 1997-10-12 | 2001-09-25 | Bayer Aktiengesellschaft | Osmotic medicament releasing system |
US5998406A (en) * | 1997-11-12 | 1999-12-07 | Pharmacia & Upjohn Company | Oxazolidinone derivatives and pharmaceutical compositions |
US6265178B1 (en) * | 1997-12-05 | 2001-07-24 | Pharmacia & Upjohn Company | Assay for determining oxazolidinone antibiotics having minimum monoamine oxidase inhibitory activity |
US20040102450A1 (en) * | 1998-01-27 | 2004-05-27 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
US20010029351A1 (en) * | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US6251869B1 (en) * | 1998-05-18 | 2001-06-26 | Pharmacia & Upjohn Company | Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
US6805881B1 (en) * | 1998-09-18 | 2004-10-19 | Bayer Aktiengesellschaft | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
US6281210B1 (en) * | 1999-12-14 | 2001-08-28 | Pharmacia & Upjohn Company | Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
US20010046987A1 (en) * | 1999-12-21 | 2001-11-29 | Hester Jackson B. | Oxazolidinones having a sulfoximine functionality |
US20080200674A1 (en) * | 1999-12-24 | 2008-08-21 | Bayer Healthcare Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US20080090815A1 (en) * | 1999-12-24 | 2008-04-17 | Alexander Straub | Substituted oxazolidinones and their use in the field of blood coagulation |
US7157456B2 (en) * | 1999-12-24 | 2007-01-02 | Bayer Healthcare Ag | Substituted oxazolidinones and their use in the field of blood coagulation |
US20060258724A1 (en) * | 1999-12-24 | 2006-11-16 | Alexander Straub | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation |
US20030153610A1 (en) * | 1999-12-24 | 2003-08-14 | Alexander Straub | Substituted oxazolidinones and their in the field of blood coagulation |
US6818243B2 (en) * | 1999-12-28 | 2004-11-16 | Ajinomoto Co., Inc. | Crystals of aspartame derivative |
US7034017B2 (en) * | 2001-02-09 | 2006-04-25 | Bayer Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US20050261502A1 (en) * | 2001-03-05 | 2005-11-24 | Ulrich Rosentreter | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof |
US20040162427A1 (en) * | 2001-03-07 | 2004-08-19 | Ulrich Rosentreter | Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
US20060154969A1 (en) * | 2001-03-07 | 2006-07-13 | Ulrich Rosentreter | Adenosine receptor selective modulators |
US7129255B2 (en) * | 2001-03-30 | 2006-10-31 | Bayer Aktiengesellschaft | Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor |
US7078417B2 (en) * | 2001-03-30 | 2006-07-18 | Bayer Aktiengesellschaft | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations |
US20040242660A1 (en) * | 2001-06-20 | 2004-12-02 | Alexander Straub | Substituted oxazolidinones for combinational therapy |
US7045631B2 (en) * | 2001-07-16 | 2006-05-16 | Bayer Aktiengesellschaft | Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
US20050064006A1 (en) * | 2001-10-24 | 2005-03-24 | Bayer Aktiengesellschaft | Stents |
US7109218B2 (en) * | 2001-12-11 | 2006-09-19 | Bayer Healthcare Ag | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
US20030161882A1 (en) * | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
US20080026057A1 (en) * | 2003-11-27 | 2008-01-31 | Bayer Healthcare Ag | Process for the Preparation of a Solid, Orally Administrable Pharmaceutical Composition |
US20050182055A1 (en) * | 2004-01-15 | 2005-08-18 | Bayer Healthcare Ag | Preparation process |
US7351823B2 (en) * | 2004-01-15 | 2008-04-01 | Bayer Healthcare Ag | Preparation process |
US20070026065A1 (en) * | 2004-12-24 | 2007-02-01 | Bayer Healthcare Ag | Solid, modified-release pharmaceutical dosage forms which can be administered orally |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530505B2 (en) | 1999-12-24 | 2013-09-10 | Bayer Intellectual Property Gmbh | Substituted oxazolidinones and their use in the field of blood coagulation |
US7585860B2 (en) | 1999-12-24 | 2009-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US20080090815A1 (en) * | 1999-12-24 | 2008-04-17 | Alexander Straub | Substituted oxazolidinones and their use in the field of blood coagulation |
US20080200674A1 (en) * | 1999-12-24 | 2008-08-21 | Bayer Healthcare Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US20100137274A1 (en) * | 1999-12-24 | 2010-06-03 | Bayer Schering Pharma Ag | Substituted oxazolidinones and their use in the field of blood coagulation |
US8822458B2 (en) | 1999-12-24 | 2014-09-02 | Bayer Intellectual Property Gmbh | Substituted oxazolidinones and their use in the field of blood coagulation |
US8129378B2 (en) | 1999-12-24 | 2012-03-06 | Bayer Pharma Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US7576111B2 (en) | 1999-12-24 | 2009-08-18 | Bayer Schering Pharma Ag | Substituted oxazolidinones and their use in the field of blood coagulation |
US7592339B2 (en) | 1999-12-24 | 2009-09-22 | Bayer Schering Pharma Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US7767702B2 (en) | 2001-06-20 | 2010-08-03 | Bayer Schering Pharma Aktiengesellschaft | Substituted oxazolidinones for combinational therapy |
US20100267685A1 (en) * | 2001-06-20 | 2010-10-21 | Bayer Schering Pharma Aktiengesellschaft | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones |
US20040242660A1 (en) * | 2001-06-20 | 2004-12-02 | Alexander Straub | Substituted oxazolidinones for combinational therapy |
US20100081807A1 (en) * | 2003-01-07 | 2010-04-01 | Bayer Healthcare Ag | Method for producing 5-cloro-n-(methyl)-2-thiophenecarboxamide |
US8106192B2 (en) | 2003-01-07 | 2012-01-31 | Bayer Pharma Aktiengesellschaft | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
US9415053B2 (en) | 2003-11-27 | 2016-08-16 | Bayer Intellectual Property Gmbh | Solid, orally administrable pharmaceutical composition |
US9402851B2 (en) | 2003-11-27 | 2016-08-02 | Bayer Intellectual Property Gmbh | Process for the preparation of a solid, orally administrable pharmaceutical composition |
US20090048173A1 (en) * | 2004-05-13 | 2009-02-19 | Wolfgang Eisert | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors |
US20070026065A1 (en) * | 2004-12-24 | 2007-02-01 | Bayer Healthcare Ag | Solid, modified-release pharmaceutical dosage forms which can be administered orally |
US9539218B2 (en) | 2005-01-31 | 2017-01-10 | Bayer Intellectual Property Gmbh | Prevention and treatment of thromboembolic disorders |
US20090004265A1 (en) * | 2005-01-31 | 2009-01-01 | Bayer Healthcare Ag | Prevention and Treatment of Thromboembolic Disorders |
US20090036504A1 (en) * | 2005-09-23 | 2009-02-05 | Bayer Healthcare Ag | 2-Aminoethoxyacetic Acid Derivatives and Their Use |
US7932278B2 (en) | 2005-09-23 | 2011-04-26 | Bayer Schering Pharma Aktiengesellschaft | 2-aminoethoxyacetic acid derivatives and their use |
US20100152189A1 (en) * | 2005-10-04 | 2010-06-17 | Bayer Healthcare Ag | Novel polymorphous form and the amorphous form of 5-chloro-n-({ (5s)-2-oxo-3[4-(3-oxo-4-morpholinyl(-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
US20080306070A1 (en) * | 2005-10-04 | 2008-12-11 | Bayer Healthcare Ag | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders |
US8586082B2 (en) | 2005-10-04 | 2013-11-19 | Bayer Intellectual Property Gmbh | Solid orally administerable pharmaceutical dosage forms with rapid active principle release |
US8188270B2 (en) | 2005-10-04 | 2012-05-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
US20100120718A1 (en) * | 2006-11-02 | 2010-05-13 | Bayer Schering Pharma Aktiengesellschaft | Combination therapy of substituted oxazolidinones |
US8101609B2 (en) | 2009-04-28 | 2012-01-24 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
US20100273798A1 (en) * | 2009-04-28 | 2010-10-28 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US20100273790A1 (en) * | 2009-04-28 | 2010-10-28 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
CN102822167A (en) * | 2010-01-04 | 2012-12-12 | 埃南蒂亚有限公司 | Process for the preparation of rivaroxaban and intermediates thereof |
CN102753537A (en) * | 2010-02-10 | 2012-10-24 | 桑多斯股份公司 | Method for the preparation of rivaroxaban |
WO2012051692A1 (en) | 2010-10-18 | 2012-04-26 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US9556163B2 (en) | 2011-05-06 | 2017-01-31 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of a rivaroxaban and intermediates formed in said process |
WO2013152168A1 (en) | 2012-04-06 | 2013-10-10 | Indiana University Research And Technology Corporation | Processes for preparing rivaroxaban |
CN104487436A (en) * | 2012-05-02 | 2015-04-01 | 信谊实验室有限公司 | Improved process for preparing rivaroxaban using novel intermediates |
US9376427B2 (en) | 2012-05-02 | 2016-06-28 | Symed Labs Limited | Process for preparing rivaroxaban using intermediates |
WO2013164833A1 (en) * | 2012-05-02 | 2013-11-07 | Symed Labs Limited | Improved process for preparing rivaroxaban using novel intermediates |
CN104487436B (en) * | 2012-05-02 | 2017-05-24 | 信谊实验室有限公司 | Improved process for preparing rivaroxaban using intermediates |
CN103864771A (en) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | Rivaroxaban preparation method |
CN103351385A (en) * | 2013-06-28 | 2013-10-16 | 浙江燎原药业有限公司 | Preparation method for rivaroxaban intermediate |
CN103524447A (en) * | 2013-10-24 | 2014-01-22 | 山东铂源药业有限公司 | Method for synthesizing rivaroxaban intermediate 4-(4-aminophenyl)-3-molindone |
CN103724336A (en) * | 2013-12-24 | 2014-04-16 | 悦康药业集团有限公司 | Synthesis method of novel anticoagulation drug |
WO2016045586A1 (en) * | 2014-09-26 | 2016-03-31 | 华北制药集团新药研究开发有限责任公司 | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof |
KR20170055551A (en) * | 2014-09-26 | 2017-05-19 | 놀스 차이나 파머수티컬 뉴 드럭 알앤디 씨오., 엘티디 | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof |
US10106557B2 (en) | 2014-09-26 | 2018-10-23 | North China Pharmaceutical New Drug R&D Co., Ltd. | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof |
KR102485412B1 (en) | 2014-09-26 | 2023-01-05 | 놀스 차이나 파머수티컬 뉴 드럭 알앤디 씨오., 엘티디 | Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof |
CN109280053A (en) * | 2018-10-11 | 2019-01-29 | 东南大学 | Razaxaban oxazolidine impurity reference substance and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2360097T3 (en) | 2011-05-31 |
DE50313496D1 (en) | 2011-04-07 |
CA2512504A1 (en) | 2004-07-22 |
WO2004060887A1 (en) | 2004-07-22 |
JP4667044B2 (en) | 2011-04-06 |
EP1583761A1 (en) | 2005-10-12 |
US20100081807A1 (en) | 2010-04-01 |
EP1583761B1 (en) | 2011-02-23 |
JP2006513227A (en) | 2006-04-20 |
CA2512504C (en) | 2012-08-21 |
DE10300111A1 (en) | 2004-07-15 |
US8106192B2 (en) | 2012-01-31 |
AU2003296728A1 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8106192B2 (en) | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | |
US7351823B2 (en) | Preparation process | |
JP5274725B2 (en) | Preparation method of rivaroxaban | |
JP6325978B2 (en) | Process for the preparation of rivaroxaban and intermediates formed in the process | |
US20150011756A1 (en) | Process for preparation of rivaroxaban and intermediates thereof | |
US11891384B2 (en) | Process for the preparation of Rivaroxaban involving novel intermediate | |
US20110288294A1 (en) | Preparation process for an inhibitor of a blood clotting factor | |
EP2844654A1 (en) | Improved process for preparing rivaroxaban using novel intermediates | |
WO2012041263A2 (en) | A method of manufacturing 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]- l,3-oxazolidin-5-yl}methyl)-lh-isoindol-l,3(2h)-dione with a high optical purity | |
KR100814100B1 (en) | Alkylcarbamoyl naphthalenyloxyprophenyl hydroxybenzamide derivatives having inhibitory activity against histone deacetylase, method for the preparation thereof, and anticancer composition comprising the same | |
JP2009518380A (en) | Preparation of 2-chloroethoxy-acetic acid-N, N-dimethylamide | |
US20170267669A1 (en) | Process for the Preparation of Rivaroxaban | |
KR101811123B1 (en) | Novel morpholine diphosphate salt, and method for manufacturing high purity rivaroxaban using same | |
KR101206598B1 (en) | Production method | |
MXPA06007902A (en) | Production method | |
JPS589106B2 (en) | Fukusokanshikikagobutsunoseiho |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER HEALTHCARE, AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THOMAS, CHRISTIAN R.;REEL/FRAME:017717/0964 Effective date: 20050609 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AG, GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022520/0150 Effective date: 20081230 Owner name: BAYER SCHERING PHARMA AG,GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022520/0150 Effective date: 20081230 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AG, GERMANY Free format text: CORRECTION IN COVER SHEET PREVIOUSLY RECORDED;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022575/0337 Effective date: 20081230 Owner name: BAYER SCHERING PHARMA AG,GERMANY Free format text: CORRECTION IN COVER SHEET PREVIOUSLY RECORDED;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:022575/0337 Effective date: 20081230 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |